gefitinib has been researched along with incb-018424 in 7 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (incb-018424) | Trials (incb-018424) | Recent Studies (post-2010) (incb-018424) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,487 | 185 | 1,451 |
| Protein | Taxonomy | gefitinib (IC50) | incb-018424 (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.12 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0573 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.0001 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0327 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.0962 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.3547 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Burov, A; Dalina, A; Funikov, S; Grigorieva, E; Karpov, V; Lebedev, T; Leonova, O; Morozov, A; Popenko, V; Prassolov, V; Rezvykh, A; Shyrokova, E; Spasskaya, D; Spirin, P; Vagapova, E | 1 |
7 other study(ies) available for gefitinib and incb-018424
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Fluorescence; Gefitinib; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Interferon-gamma; Nitriles; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazoles; Pyrimidines; Tumor Necrosis Factor-alpha; Vincristine | 2021 |